Steven W Ludmerer
Overview
Explore the profile of Steven W Ludmerer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
659
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xiao D, Dai X, Liu H, He S, Shi Z, Ludmerer S, et al.
Bioorg Med Chem Lett
. 2020 Feb;
30(7):127004.
PMID: 32061500
In a lead optimization effort towards NS5B NNI inhibitors, two multi-step parallel libraries were designed and successfully synthesized. Through this effort we discovered compound 9B, which achieved rigorous and delicate...
2.
Liu H, Dai X, He S, Brockunier L, Marcantonio K, Ludmerer S, et al.
Bioorg Med Chem Lett
. 2018 Nov;
29(24):126104.
PMID: 30389294
Hepatitis C virus (HCV) NS5B polymerase is a prime target for the development of direct-acting antiviral drugs for the treatment of chronic HCV infection. Several novel and potent HCV NS5B...
3.
McComas C, Palani A, Chang W, Holloway M, Lesburg C, Li P, et al.
ChemMedChem
. 2017 Jul;
12(17):1436-1448.
PMID: 28741898
Studies directed at developing a broadly acting non-nucleoside inhibitor of HCV NS5B led to the discovery of a novel structural class of 5-aryl benzofurans that simultaneously interact with both the...
4.
Ludmerer S, Hirano T, Black S, Howe A, Chang W, Takase A, et al.
Antiviral Res
. 2016 Mar;
130:118-29.
PMID: 26947564
Unlabelled: In the phase III registration studies conducted in Japan, Japanese HCV gt1 patients administered vaniprevir 300 mg twice daily plus pegylated interferon/ribavirin for 12 or 24 weeks achieved SVR24...
5.
Hayashi N, Nakamuta M, Takehara T, Kumada H, Takase A, Howe A, et al.
J Gastroenterol
. 2015 Sep;
51(4):390-403.
PMID: 26403160
Background: Vaniprevir is a potent macrocyclic hepatitis C virus (HCV) nonstructural protein 3/4A protease inhibitor. This phase III study evaluated the safety and efficacy of vaniprevir in combination with peginterferon...
6.
Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir
Liu R, Curry S, McMonagle P, Yeh W, Ludmerer S, Jumes P, et al.
Antimicrob Agents Chemother
. 2015 Aug;
59(11):6922-9.
PMID: 26303801
Elbasvir is an investigational NS5A inhibitor with in vitro activity against multiple HCV genotypes. Antiviral activity of elbasvir was measured in replicons derived from wild-type or resistant variants of genotypes...
7.
Rudd M, Butcher J, Nguyen K, McIntyre C, Romano J, Gilbert K, et al.
ChemMedChem
. 2015 Mar;
10(4):727-35.
PMID: 25759009
With the goal of identifying inhibitors of hepatitis C virus (HCV) NS3/4a protease that are potent against a wide range of genotypes and clinically relevant mutant viruses, several subseries of...
8.
Howe A, Black S, Curry S, Ludmerer S, Liu R, Barnard R, et al.
Clin Infect Dis
. 2014 Oct;
59(12):1657-65.
PMID: 25266289
Background: Virologic failure following treatment of hepatitis C virus (HCV) genotype 1 with direct-acting antiviral agents is often accompanied by the emergence of resistant variants. MK-5172 is an investigational once-daily...
9.
Harper S, McCauley J, Rudd M, Ferrara M, DiFilippo M, Crescenzi B, et al.
ACS Med Chem Lett
. 2014 Jun;
3(4):332-6.
PMID: 24900473
A new class of HCV NS3/4a protease inhibitors containing a P2 to P4 macrocyclic constraint was designed using a molecular modeling-derived strategy. Building on the profile of previous clinical compounds...
10.
Rudd M, McCauley J, Butcher J, Romano J, McIntyre C, Nguyen K, et al.
ACS Med Chem Lett
. 2014 Jun;
2(3):207-12.
PMID: 24900304
The discovery of MK-1220 is reported along with the development of a series of HCV NS3/4A protease inhibitors containing a P2 to P4 macrocyclic constraint with improved preclinical pharmacokinetics. Optimization...